LONDON, Oct. 5, 2016 /PRNewswire/ -- Market barriers cause net share loss for 5 major RCC treatments in Europe.
Is your brand one of them?We researched 8 renal cell carcinoma (RCC) treatments to see what happens to their share of the European market when oncologists can't prescribe freely. The result: 5 of those brands saw a net loss. But 3 of them made significant
net gains. Is your brand one of them?You'll learn how market barriers affect share for 8 major treatments from Bayer/Amgen, Novartis, Pfizer, and Roche.Plus you'll see which brands your brand is losing share to, which ones you're taking it from, and why—information you can use to compete more effectively.Get Answers to Key Questions about RCC Drug BrandsAfinitor (everolimus; Novartis): Afinitor takes market share from only two brands. Which two?Avastin (bevacizumab; Roche): Which brand takes more than twice as much share from Avastin as any other?Inlyta (axitinib; Pfizer): Would eliminating market barriers help Inlyta catch up to Afinitor?Nexavar (sorafenib; Bayer/Amgen): Are doctors who don't prescribe either brand more likely to consider Nexavar or Inlyta?Proleukin (aldesleukin; Novartis): Which two barriers do more doctors experience with Proleukin than any other brand? Sutent (sunitinib; Pfizer): Which barrier is responsible for nearly a quarter of Sutent's impressive share gain?Torisel (temsirolimus; Pfizer): Only one market barrier earns Torisel a net share gain. Which one?Votrient (pazopanib; Novartis): Votrient and Afinitor are just about equally prescribed. Which brand has the edge in market share?Top TakeawaysBarriers cost most brands market share: Five of the eight surveyed brands saw a net share loss due to barriers. Only three saw net gains.Eliminating barriers would tighten up the market: Especially the top of the market, where it would make a big dent in the #1 brand's lead.Most brands are heavily prescribed: A majority of doctors prescribe nearly all of the brands surveyed. The most prescribed brand has almost a 10% lead over its nearest rival.Clear market share winner: of the three brands that gain share due to market barriers, one gains more than twice as much as the closest competitor.Barrier effect varies widely: The number of doctors who experience each market barrier varies widely from brand to brand.Reimbursement and guidelines have the greatest impact: barriers related to reimbursement, patient type restrictions, and guidelines affect more prescriptions than any others.Brand awareness is high: With one exception, no more than 1% of doctors surveyed were unaware of any given brand.Overall market access is good: In Europe, market barriers affect less than 20% of prescription decisions.Exploring Market Access IssuesMarket Access Impact: RCC explores key issues affecting RCC drug manufacturers. You'll learn:How barriers affect market access:What brands do doctors prescribe the most?How many prescriptions do barriers affect?Which barriers have the biggest effect?How barriers affect your brand:How many doctors prescribe your brand? How many don't, but would consider it?Why don't doctors prescribe your brand? What do they prescribe instead?Which competing brands does your brand take market share from?A Report Based on Expert KnowledgeWe surveyed 150 medical oncologists—30 from each EU5 country (France
, UK)—chosen from the largest community of validated physicians in the world.All respondents have:Been practicing for 2+ yearsPrescribed at least one of the listed productsSeen at least 5 patients with melanoma in total in the last monthWe conducted the survey between April 4th and 11th, 2016
.Download the full report: https://www.reportbuyer.com/product/3866843/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com
For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/market-access-impact-renal-cell-carcinoma-eu5-300340251.html